DEF: Modular Medical Seeks Shareholder Approval for Equity Plan Expansion and Director Elections at 2025 Annual Meeting

Modular Medical, Inc. is holding its 2025 Annual Meeting of Shareholders on February 28, 2025, to vote on key proposals including the election of seven directors, an increase in the company's equity incentive plan, and the ratification of its independent auditor.

Summary

• Modular Medical, Inc. will hold its 2025 Annual Meeting of Shareholders virtually on February 28, 2025.
• Shareholders will vote on the election of seven directors to the board.
• A proposal to amend the 2017 Equity Incentive Plan to increase the number of shares available for issuance by 3,000,000 will be voted on.
• The ratification of Farber Hass Hurley LLP as the company's independent registered public accounting firm for the fiscal year ending March 31, 2025, is also on the agenda.
• The record date for shareholders entitled to vote at the meeting was January 17, 2025.
• As of the record date, there were 40,665,220 shares of common stock issued and outstanding, held by approximately 66 record holders.
• The company is seeking to increase the share pool to provide adequate shares for at least the next two years.
• The company acknowledges the need to balance shareholder concerns over dilution with the need to attract and retain employees.
• The company issued 5,450,573 shares in a public offering in November 2024, raising approximately $8.2 million.
• The company expects to need additional capital in the future to commercialize its initial pump product.

Sentiment

Score: 4

Explanation: The document highlights the company's need for additional capital and the substantial doubt about its ability to continue as a going concern, which are significant negative factors. While there are positive aspects such as the board's experience and the company's efforts to manage corporate governance, the overall tone is cautious and reflects the challenges the company is facing.

Positives

• The company is taking steps to ensure it has sufficient shares available for future equity grants.
• The company is actively managing its corporate governance through board committees.
• The company is transparent about its need for additional capital to support its growth.
• The company has a clear process for shareholders to communicate with the board.

Negatives

• The company acknowledges substantial doubt about its ability to continue as a going concern due to operating losses and negative cash flows.
• The company anticipates significant dilution from future capital raises.
• The company's compensation committee did not hold any meetings during the fiscal year ended March 31, 2024.
• The company has a history of amending the 2017 Equity Incentive Plan to increase the number of shares available for issuance.

Risks

• The company faces the risk of not being able to attract and retain employees if the equity plan amendment is not approved.
• The company's future success is dependent on its ability to raise additional capital.
• The company's financial position is precarious, with substantial doubt about its ability to continue as a going concern.
• The company's share price may be negatively impacted by future dilution.

Future Outlook

The company expects to need to raise additional capital through debt or equity arrangements in the foreseeable future to commercialize its initial pump product.

Management Comments

• On behalf of the Board of Directors, thank you for your continued confidence and investment in the Company.
• We encourage you to read all of the information in the proxy statement and vote your shares as soon as possible.

Industry Context

The company operates in the medical device industry, specifically focusing on insulin pump technology, which is a competitive market with established players. The company's need for additional capital and its focus on commercializing its initial pump product suggests it is in a growth phase, facing the challenges of scaling up and competing with larger, more established companies.

Comparison to Industry Standards

• The company's executive compensation practices are being benchmarked against other companies in the industry using data from San Diego Human Resources Consulting.
• The company's board includes members with experience at companies like Insulet and Tandem Diabetes Care, which are direct competitors in the insulin pump market.
• The company's reliance on equity-based compensation is common in the medical device industry, particularly for early-stage companies.
• The company's need for additional capital is typical for companies in the development stage of medical devices.

Related Party Transactions

• Manchester Explorer purchased 900,000 shares in the 2024 Offering for $990,000.
• The company paid approximately $137,000 to Mr. DiPerna's daughter, an employee of the company.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from future capital raises.
• Employees may be impacted by the company's ability to retain and incentivize them through equity awards.
• The company's ability to commercialize its product will impact its customers and the broader market.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will proceed with the Annual Meeting on February 28, 2025.
• The company will continue to seek additional capital to support its operations and commercialization efforts.

Key Dates

Keywords

Annual Meeting, Shareholders, Equity Incentive Plan, Board of Directors, Director Election, Independent Auditor, Capital Raise, Dilution, Stock Options, Corporate Governance